The firm is a leading European venture capital firm investing in early- and growth-stage life science companies. The firm focuses on biotechnology, therapeutics, medical technology, diagnostics, digital health, and life science tools. The firm has a long track record of supporting innovative companies as they translate scientific breakthroughs into high-growth businesses. To date, the firm has invested in more than 60 life science companies, including multiple successful acquisitions by large pharmaceutical and medical technology companies. Initial investment sizes typically range from EUR 5–10 million, with the potential to invest up to EUR 20 million over the life of an investment.
The firm invests primarily in Europe and selectively in the United States across five broad areas: therapeutics, medtech, diagnostics, digital health, and biotechnology and R&D tools. Within therapeutics, the firm focuses on early-stage companies with preclinical proof-of-concept data or programs approaching clinical entry, with a preference for highly innovative technology platforms and opportunities supported by early clinical data. In other sectors, the firm prefers companies with product candidates supported by strong intellectual property that are approaching regulatory approval or companies that have already launched a first product and achieved early market traction.
From a company and management team perspective, the firm typically seeks a board seat and places strong emphasis on experienced, high-quality management teams. At the same time, the firm actively supports highly talented entrepreneurs and works closely with portfolio companies to help drive strategic, operational, and commercial execution.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment